i-SENS Inc (099190) - Total Liabilities
Based on the latest financial reports, i-SENS Inc (099190) has total liabilities worth ₩234.55 Billion KRW (≈ $158.95 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
i-SENS Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how i-SENS Inc's total liabilities have evolved over time, based on quarterly financial data. See i-SENS Inc (099190) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
i-SENS Inc Competitors by Total Liabilities
The table below lists competitors of i-SENS Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Niu Technologies
NASDAQ:NIU
|
USA | $2.41 Billion |
|
Sebo Manufacturing Engineering & Construction Corp
KQ:011560
|
Korea | ₩136.26 Billion |
|
Tri Ocean Textile Co Ltd
TW:1472
|
Taiwan | NT$3.12 Billion |
|
Dune Acquisition Corporation II Class A Ordinary Shares
NASDAQ:IPOD
|
USA | $5.85 Million |
|
Heran Co Ltd
TW:5283
|
Taiwan | NT$3.23 Billion |
|
Financiera Independencia S.A.B. de C.V. SOFOM E.N.R
MX:FINDEP
|
Mexico | MX$6.28 Billion |
|
Temapol Polimer Plastik ve Insaat Sanayi Ticaret AS
IS:TMPOL
|
Turkey | TL1.15 Billion |
|
Lindsay Australia Ltd
AU:LAU
|
Australia | AU$553.18 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down i-SENS Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see i-SENS Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how i-SENS Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for i-SENS Inc (2012–2025)
The table below shows the annual total liabilities of i-SENS Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩239.34 Billion ≈ $162.20 Million |
-3.45% |
| 2024-12-31 | ₩247.89 Billion ≈ $167.99 Million |
+26.91% |
| 2023-12-31 | ₩195.32 Billion ≈ $132.37 Million |
+19.27% |
| 2022-12-31 | ₩163.76 Billion ≈ $110.98 Million |
+1.81% |
| 2021-12-31 | ₩160.85 Billion ≈ $109.00 Million |
+83.75% |
| 2020-12-31 | ₩87.54 Billion ≈ $59.32 Million |
+22.46% |
| 2019-12-31 | ₩71.48 Billion ≈ $48.44 Million |
+0.50% |
| 2018-12-31 | ₩71.12 Billion ≈ $48.20 Million |
-0.22% |
| 2017-12-31 | ₩71.28 Billion ≈ $48.31 Million |
+9.00% |
| 2016-12-31 | ₩65.39 Billion ≈ $44.32 Million |
+36.87% |
| 2015-12-31 | ₩47.78 Billion ≈ $32.38 Million |
+6.88% |
| 2014-12-31 | ₩44.70 Billion ≈ $30.29 Million |
+20.50% |
| 2013-12-31 | ₩37.10 Billion ≈ $25.14 Million |
+57.12% |
| 2012-12-31 | ₩23.61 Billion ≈ $16.00 Million |
-- |
About i-SENS Inc
i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe.… Read more